Table 1 Circulating proteins and the development of liver metastasis—the separate cohorts.

From: The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer

 

SAM analysis

Univariable Cox regression analysis

D

Q

N (%)

HR (95% CI)a

P

Investigation cohortb

 CXCL2

2.14

0

121 (99.2)

1.001 (1.000–1.002)

0.011

 ANGPT2

1.55

0

121 (99.2)

1.000 (1.000–1.000)

0.833

 sCD40

1.51

0

121 (99.2)

1.004 (1.001–1.007)

0.007

 TNFRSF10B

1.35

0

121 (99.2)

1.000 (0.998–1.002)

0.904

 FLT3LG

0.95

7.73

116 (95.1)

0.996 (0.982–1.011)

0.618

 VEGFA

0.88

7.73

101 (82.8)

1.000 (1.000–1.000)

0.849

Validation cohort 1

 CXCL2

  

79 (100)

1.001 (0.999–1.002)

0.249

 sCD40

  

79 (100)

1.003 (1.000–1.006)

0.040

Validation cohort 2c

 sCD40

  

129 (95.6)

1.001 (1.000–1.002)

0.029

Validation cohort 3d

 sCD40

  

55 (93.2)

1.003 (1.000–1.006)

0.044

  1. ANGPT2 angiopoietin-2, CI confidence interval, CXCL2 C–X-C motif chemokine ligand 2, D likelihood score, FLT3LG fms-related receptor tyrosine kinase 3 ligand, HR hazard ratio, Q false discovery rate, SAM Significance Analysis for Microarrays, sCD40 soluble cluster of differentiation molecule 40, TNFRSF10B tumour necrosis factor superfamily member 10B, VEGFA vascular endothelial growth factor A.
  2. aHR above 1 indicates enhanced probability for the event. Patients were omitted from the analyses because they developed lung metastasis before the first occurrence of liver metastasis: bone cand additional three patients without metastatic disease who were lost to follow-up.
  3. dAdditional two patients who died without metastatic disease.
Back to article page